Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2022 1
2023 1
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness and Tolerability of the Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily in Patients with Type 2 Diabetes in Real Life: The INTENSIFY Study.
Gorgojo-Martinez JJ, Ferreira-Ocampo PJ, Galdón Sanz-Pastor A, Cárdenas-Salas J, Antón-Bravo T, Brito-Sanfiel M, Almodóvar-Ruiz F. Gorgojo-Martinez JJ, et al. Among authors: galdon sanz pastor a. J Clin Med. 2023 Jun 25;12(13):4248. doi: 10.3390/jcm12134248. J Clin Med. 2023. PMID: 37445283 Free PMC article.
Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment: Relationship Between Antibodies and Severity of Thyroid Dysfunction.
Miguélez González M, Galdón Sanz-Pastor A, Áñez Gómez R, Brox Torrecilla N, Muñoz Moreno D, González Fernández L, Maricel Rivas A, López Guerra A, Álvarez R, Arranz JÁ, Márquez Rodas I, Escudero V, Sanjurjo M, Martín Vallejo J, Martín M, González Albarrán O. Miguélez González M, et al. Among authors: galdon sanz pastor a. Endocr Metab Immune Disord Drug Targets. 2024 Feb 14. doi: 10.2174/0118715303280679240206100137. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 38362680
Are New Ultra-Rapid-Acting Insulins Associated with Improved Glycemic Control and Reduced Hypoglycemia in Comparison to Conventional Rapid-Acting Insulins for Individuals with Type 1 and Type 2 Diabetes? A Systematic Review and Meta-Analysis.
Villar-Taibo R, Galdón Sanz-Pastor A, Fernández-Rubio E, Barajas Galindo D, Simó Servat A, Ampudia-Blasco FJ. Villar-Taibo R, et al. Among authors: galdon sanz pastor a. Diabetes Technol Ther. 2024 Apr 15. doi: 10.1089/dia.2023.0524. Online ahead of print. Diabetes Technol Ther. 2024. PMID: 38502158